Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
penpulimab + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Penpulimab + oxaliplatin + capecitabine is a chemo-immunotherapy combination regimen being evaluated for the treatment of advanced solid tumors, particularly gastric and gastroesophageal junction (GEJ) cancers. The regimen consists of **penpulimab** (AK105), a humanized IgG1 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor T-cell activity, combined with the **XELOX** (or CAPOX) chemotherapy doublet. XELOX includes **oxaliplatin**, a platinum-based cytotoxic agent that induces DNA cross-linking, and **capecitabine**, an oral fluoropyrimidine prodrug that is converted to 5-fluorouracil (5-FU) to inhibit DNA synthesis. This combination is often studied as a backbone therapy in clinical trials alongside novel agents such as LM-108 (an anti-CCR8 antibody) to improve outcomes in patients with advanced gastrointestinal malignancies.
- Brand names
- Anniko + Eloxatin + Xeloda
- Other names
- enpulimab + oxaliplatin + capecitabinepenpulimab + XELOXpenpulimab + CAPOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on penpulimab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on penpulimab + oxaliplatin + capecitabine.